Associations between lifetime classic psychedelic use and markers of physical health

被引:48
作者
Simonsson, Otto [1 ]
Sexton, James D. [2 ]
Hendricks, Peter S. [3 ]
机构
[1] Univ Oxford, Dept Sociol, 42-43 Pk End St, Oxford OX1 2JD, England
[2] Imperial Coll London, Dept Brain Sci, London, England
[3] Univ Alabama Birmingham, Dept Hlth Behav, Birmingham, AL USA
关键词
Classic psychedelics; psilocybin; LSD; health; body mass index; cancer; heart disease; MENTAL-HEALTH; POPULATION; PSILOCYBIN; MORTALITY; DIMETHYLTRYPTAMINE; ALCOHOL; TOBACCO; DRUGS; AGE;
D O I
10.1177/0269881121996863
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: In recent years, there has been significant research on the mental health effects of classic psychedelic use, but there is very little evidence on how classic psychedelics might influence physical health. Aims: The purpose of the present study was to investigate the associations between lifetime classic psychedelic use and markers of physical health. Methods: Using data from the National Survey on Drug Use and Health (2015-2018) with 171,766 (unweighted) adults aged 18 or above in the United States, the current study examined the associations between lifetime classic psychedelic use and three markers of physical health (self-reported overall health, body mass index, and heart condition and/or cancer in the past 12 months) while controlling for a range of covariates. Results: Respondents who reported having tried a classic psychedelic at least once in their lifetime had significantly higher odds of greater self-reported overall health and significantly lower odds of being overweight or obese versus having a normal weight. The association between lifetime classic psychedelic use and having a heart condition and/or cancer in the past 12 months approached conventional levels of significance, with lower odds of having a heart condition and/or cancer in the past 12 months for respondents who had tried a classic psychedelic at least once. Conclusion: The results of the present study suggest that classic psychedelics may be beneficial to physical health. Future research should investigate the causal effects of classic psychedelics on physical health and evaluate possible mechanisms.
引用
收藏
页码:447 / 452
页数:6
相关论文
共 52 条
[1]   Long-term effects of psychedelic drugs: A systematic review [J].
Aday, Jacob S. ;
Mitzkovitz, Cayla M. ;
Bloesch, Emily K. ;
Davoli, Christopher C. ;
Davis, Alan K. .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2020, 113 :179-189
[2]  
[Anonymous], 2019, 2018 National Survey on Drug Use and Health: Methodological summary and definitions
[3]   The Australian drug harms ranking study [J].
Bonomo, Yvonne ;
Norman, Amanda ;
Biondo, Sam ;
Bruno, Raimondo ;
Daglish, Mark ;
Dawe, Sharon ;
Egerton-Warburton, Diana ;
Karro, Jonathan ;
Kim, Charles ;
Lenton, Simon ;
Lubman, Dan I. ;
Pastor, Adam ;
Rundle, Jill ;
Ryan, John ;
Gordon, Paul ;
Sharry, Patrick ;
Nutt, David ;
Castle, David .
JOURNAL OF PSYCHOPHARMACOLOGY, 2019, 33 (07) :759-768
[4]   Psilocybin with psychological support for treatment-resistant depression: six-month follow-up [J].
Carhart-Harris, R. L. ;
Bolstridge, M. ;
Day, C. M. J. ;
Rucker, J. ;
Watts, R. ;
Erritzoe, D. E. ;
Kaelen, M. ;
Giribaldi, B. ;
Bloomfield, M. ;
Pilling, S. ;
Rickard, J. A. ;
Forbes, B. ;
Feilding, A. ;
Taylor, D. ;
Curran, H. V. ;
Nutt, D. J. .
PSYCHOPHARMACOLOGY, 2018, 235 (02) :399-408
[5]   Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study [J].
Carhart-Harris, Robin L. ;
Bolstridge, Mark ;
Rucker, James ;
Day, Camilla M. J. ;
Erritzoe, David ;
Kaelen, Mendel ;
Bloomfield, Michael ;
Rickard, James A. ;
Forbes, Ben ;
Feilding, Amanda ;
Taylor, David ;
Pilling, Steve ;
Curran, Valerie H. ;
Nutt, David J. .
LANCET PSYCHIATRY, 2016, 3 (07) :619-627
[6]   Mental Health and Cardiovascular Disease [J].
Chaddha, Ashish ;
Robinson, Elizabeth A. ;
Kline-Rogers, Eva ;
Alexandris-Souphis, Tina ;
Rubenfire, Melvyn .
AMERICAN JOURNAL OF MEDICINE, 2016, 129 (11) :1145-1148
[7]   Association of Cigarette, Cigar, and Pipe Use With Mortality Risk in the US Population [J].
Christensen, Carol H. ;
Rostron, Brian ;
Cosgrove, Candace ;
Altekruse, Sean F. ;
Hartman, Anne M. ;
Gibson, James T. ;
Apelberg, Benjamin ;
Inoue-Choi, Maki ;
Freedman, Neal D. .
JAMA INTERNAL MEDICINE, 2018, 178 (04) :469-476
[8]   Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder A Randomized Clinical Trial [J].
Davis, Alan K. ;
Barrett, Frederick S. ;
May, Darrick G. ;
Cosimano, Mary P. ;
Sepeda, Nathan D. ;
Johnson, Matthew W. ;
Finan, Patrick H. ;
Griffiths, Roland R. .
JAMA PSYCHIATRY, 2021, 78 (05) :481-489
[9]   Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews [J].
dos Santos, Rafael G. ;
Carlos Bouso, Jose ;
Angel Alcazar-Corcoles, Miguel ;
Hallak, Jaime E. C. .
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (09) :889-902
[10]   Psychedelics as anti-inflammatory agents [J].
Flanagan, Thomas W. ;
Nichols, Charles D. .
INTERNATIONAL REVIEW OF PSYCHIATRY, 2018, 30 (04) :363-375